CD8A and neoplasm: Furthermore, inhibitors of ATR such as ceralasertib were among the first DNA damage response inhibitors shown to enhance antitumoral immune responses by modulation of both the T1IFN response in tumor cells as well as direct modulation of CD8+ T cells dysfunction (34, 55).